References
- Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer. 2015;112:1421–1427.
- Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330.
- Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532.
- Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–2028.
- Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
- Vansteenkiste J, Fehrenbacher L, Spira IA, et al. Atezolizumab monotherapy vs. docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). 14LBA. Late breaking abstract presented at the European Cancer Congress; 2015 Sep 25–29; Vienna, Austria. Available from: https://www.europeancancercongress.org/Scientific-Programme/Abstract-search#
- US FDA. Premarket Approval (PMA) for PD-L1 IHC 22C3 0070harmDx. [cited 2015 Oct 2]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150013
- US FDA. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). [cited 2015 Oct 14]. Available from: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm
- US FDA. Premarket Approval (PMA) for PD-L1 IHC 28-8 pharmDx. [cited 2015 Oct 9]. http://www.acc.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150025
- Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med. 2014;7:357–365.
- Jørgensen JT. Companion diagnostics in oncology: current status and future aspects. Oncology. 2013;85:59–68.
- Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–2520.
- Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–128.
- Campesato LF, Barroso-Sousa R, Jimenez L, et al. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget. 2015 Oct 1. [Epub ahead of print].